Cancer-associated fibroblast-derived colony-stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis.

Huang, Yutang; Wang, Xiaoqing; Wen, Chunjie; Wang, Jingchan; Zhou, Honghao; Wu, Lanxiang

Huang, Yutang; Wang, Xiaoqing; Wen, Chunjie; Wang, Jingchan; Zhou, Honghao; Wu, Lanxiang.

Afiliación

Huang Y; Institute of Life Sciences Chongqing Medical University Chongqing China.
Wang X; Institute of Life Sciences Chongqing Medical University Chongqing China.
Wen C; Institute of Life Sciences Chongqing Medical University Chongqing China.
Wang J; School of Stomatology Chongqing Medical University Chongqing China.
Zhou H; Institute of Life Sciences Chongqing Medical University Chongqing China.
Wu L; Pharmacogenetics Research Institute Institute of Clinical Pharmacology Central South University Changsha China.

MedComm (2020) ; 5(8): e653, 2024 Aug.

Article en En | MEDLINE | ID: mdl-39036343

Palabras clave

Osimertinib resistance; cancerassociated fibroblasts; colonystimulating factor 2; lung adenocarcinoma; ribosome biosynthesis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: MedComm (2020) Año: 2024 Tipo del documento: Article Pais de publicación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google